Johnson & Johnson’s announcement that it will spin off one of the industry’s oldest and largest consumer health businesses to focus on its biopharmaceutical and medical device operations came as a surprise, but J&J execs explained that the pandemic has made it recognize key differences between the divisions. And the decision follows similar efforts to slim down and tighten focus at other big pharmas such as Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc. and Sanofi.
J&J outlined a plan on 12 November to split off the health care conglomerate’s consumer health unit into a separate,...








